Innovita Biological Technology (SH:688253) Cai Jing Wang·2026-02-12 10:40Core Viewpoint - Innotech reported a significant decline in revenue and net profit for the fiscal year 2025, attributed to lower flu-like cases compared to 2024, but the company continues to invest in R&D and market expansion, particularly in international markets and new business ventures [1] Financial Performance - The total revenue for 2025 was 422 million yuan, representing a year-on-year decrease of 32.08% [1] - The net profit attributable to the parent company was 146 million yuan, down 40.84% year-on-year [1] Market and Product Development - The company faced challenges due to a decrease in flu-like cases, which significantly impacted revenue [1] - Despite these challenges, Innotech maintained high levels of investment in R&D and marketing, especially in international markets and new business areas [1] - In 2025, the company received approval for over ten new product registrations and collaborated with online platforms such as JD.com and Meituan to enhance brand recognition, laying a foundation for growth in 2026 [1]